查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961474

特发性肺纤维化市场－全球产业规模、份额、趋势、机会、预测：按药物类型、给药途径、分销管道、地区和竞争格局划分，2021-2031年

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球特发性肺纤维化市场预计将从 2025 年的 38.8 亿美元成长到 2031 年的 57.3 亿美元，复合年增长率为 6.71%。

特发性肺纤维化 (IPF) 的治疗方法包括抗纤维化药物和辅助性治疗，旨在延缓肺部不可逆疤痕的形成并维持呼吸功能。这一增长主要受全球人口老化加剧、该疾病与老化密切相关以及高解析度成像技术进步（可实现早期精准诊断）等因素所驱动。根据肺纤维化基金会 2024 年的数据，肺纤维化和间质性肺病影响超过 25 万美国人，每年新增病例约 5 万例。

市场概览
预测期 2027-2031
市场规模：2025年 38.8亿美元
市场规模：2031年 57.3亿美元
复合年增长率：2026-2031年 6.71%
成长最快的细分市场 Pirfenidone
最大的市场 北美洲

儘管存在这些积极因素，但市场扩张仍面临许多障碍。其中包括长期抗纤维化治疗的高成本，这在医保报销政策严格的地区，阻碍了患者的就医。此外，支付方严格的核准标准往往使这一经济障碍更加复杂，限制了这些延长生命的治疗方法在已开发地区和新兴地区的广泛应用。

市场驱动因素

特发性肺纤维化 (IPF) 发病率的上升是市场发展的主要驱动力，这需要更广泛地提供治疗方法并扩大患者支持基础设施。诊断技术的进步使医疗专业人员能够发现更多这种慢性进行性性肺部疾病的病例，从而增加了对长期管理策略的需求。这种日益加重的疾病负担并非区域性问题，而是全球性的健康挑战，推动了对有效治疗方法的商业性需求。例如，加拿大肺纤维化基金会于 2024 年 9 月发布的新闻稿《希望在此呼吸》(Hope Breathes Here) 指出，目前约有 3 万名加拿大人患有肺纤维化，凸显了需要护理的患者群体规模庞大。

同时，先进抗纤维化疗法的快速普及显着提升了市场价值。这些药物被定位为延缓疾病进展的标准疗法，现有药物的商业性成功推动了研发，从而形成了以疗效和安全性为核心的竞争格局。对药物介入的强劲需求也反映在财务业绩上。根据勃林格殷格翰于2024年4月发布的2023财年年度报告，其以Ofev为首的纤维化治疗产品组合的净销售额达到35亿欧元。此外，对未来创新的投资持续吸引市场，例如Vicore Pharma在2024年进行的股份增发，筹集了约7.82亿瑞典克朗，用于推进其主要候选药物的临床试验。

市场挑战

长期抗纤维化治疗的高昂费用是限制全球特发性肺纤维化（IPF）市场成长的主要经济障碍。虽然这些药物能有效延缓疾病进展，但其高昂的价格往往超出病患和医疗体系的负担能力。因此，保险公司和支付方经常设定严格的报销标准，例如要求在核准前提供肺功能受损的证明。这会延迟治疗的启动，缩小合格的患者群体，最终降低收入潜力。

这种经济负担不仅阻碍了新患者的招募，也导致了较高的治疗中断率。面对高昂的自付费用，患者被迫优先购买生活必需品而非继续治疗，导致临床疗效下降和药品销售量减少。肺纤维化基金会在2024年指出，在新的费用上限实施之前，美国联邦医疗保险受益人每年处方药的自付费用上限约为8000美元，这凸显了老年人（该疾病最易感人群）面临的沉重经济负担。这些经济压力造成了一种限制性环境，阻碍了治疗方法的广泛应用，进而阻碍了整体市场的扩张。

市场趋势

人工智慧 (AI) 与诊断影像技术的融合正在改变全球特发性肺纤维化市场，它以自动化的定量生物标记取代了主观的人工评估，从而更准确地预测疾病进展。这些人工智慧工具分析电脑断层扫描 (CT) 影像，测量肺部结构的变化，为临床医生提供可靠的数据，用于患者分层和临床试验中的个人化医疗。根据美国国立卫生研究院 (NIH) 于 2025 年 3 月发布的 ERS ​​2024 年大会亮点报告，人工智慧衍生的加权网状评分 (WRVS) 展现出优于传统检测法的预后能力，其识别高死亡风险患者的风险比为 4.55。

此外，新一代机制特异性治疗方法的出现标誌着抗纤维化治疗从广谱药物转向靶向特定病理通路（例如溶血磷脂酸信号通路）的精准药物的重大转变。这一趋势的驱动力在于迫切需要提高患者的依从性和治疗效果，而这些药物与Pirfenidone和尼达尼布等传统疗法相比，具有更高的安全性和更精准的定向。根据2025年7月发表在《胸科医师》（Chest Physician）杂誌上的报导“Admirparant II期试验结果为肺纤维化联合治疗带来希望”，在接受60毫克剂量治疗的特发性肺纤维化患者中，在研的LPA1拮抗剂admirparant使肺功能下降的相对风险降低了54%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球特发性肺纤维化市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依药物类型（Pirfenidone、尼达尼布、其他）
    • 给药途径（肠外、口服、其他）
    • 分销通路（医院药局、零售药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美特发性肺纤维化市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲特发性肺纤维化市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区特发性肺纤维化市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲特发性肺纤维化市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲特发性肺纤维化市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球特发性肺纤维化市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19233

The Global Idiopathic Pulmonary Fibrosis Market is projected to expand from USD 3.88 billion in 2025 to USD 5.73 billion by 2031, reflecting a compound annual growth rate of 6.71%. Therapeutics for Idiopathic Pulmonary Fibrosis (IPF) include antifibrotic drugs and adjunctive treatments aimed at slowing irreversible lung scarring and maintaining respiratory capacity. This growth is primarily driven by an aging global population, given the strong correlation between the disease and advanced age, as well as advancements in high-resolution imaging that allow for earlier and more precise diagnosis. Data from the Pulmonary Fibrosis Foundation in 2024 indicates that pulmonary fibrosis and interstitial lung diseases affect more than 250,000 Americans, with roughly 50,000 new diagnoses annually.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.88 Billion
Market Size 2031USD 5.73 Billion
CAGR 2026-20316.71%
Fastest Growing SegmentPirfenidone
Largest MarketNorth America

Despite these positive factors, market expansion faces a major obstacle in the form of the high cost of long-term antifibrotic treatments, which hinders patient access in healthcare systems with strict reimbursement policies. This financial hurdle, often compounded by stringent payer approval criteria, restricts the broad utilization of these life-extending therapies across both developed and emerging regions.

Market Driver

The rising prevalence of Idiopathic Pulmonary Fibrosis (IPF) acts as a key determinant of market progress, requiring a corresponding increase in therapeutic availability and patient support infrastructures. Improvements in diagnostic capabilities enable healthcare providers to detect more instances of this chronic, progressive lung condition, thereby escalating the demand for long-term management strategies. This increasing disease burden is a global health issue rather than a regional one, fueling the commercial need for effective treatments; for instance, the Canadian Pulmonary Fibrosis Foundation's 'Hope Breathes Here Press Release' in September 2024 noted that approximately 30,000 Canadians are currently living with pulmonary fibrosis, underscoring the large patient population needing care.

Concurrently, the rapid uptake of advanced antifibrotic therapies significantly boosts market value, as these medications remain the standard of care for retarding disease progression. The commercial viability of existing agents stimulates ongoing research and development, fostering a competitive landscape focused on efficacy and safety. The strong demand for pharmaceutical interventions is reflected in financial results; Boehringer Ingelheim's April 2024 'Annual Report 2023' reported net sales of 3.5 billion EUR for their fibrosis portfolio, led by Ofev. Furthermore, the market continues to attract investment for future innovations, as demonstrated by Vicore Pharma, which raised approximately 782 million SEK in a 2024 rights issue to progress its lead candidate through clinical trials.

Market Challenge

The exorbitant cost associated with long-term antifibrotic therapy represents a major economic hurdle slowing the growth of the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Although these medications effectively retard disease progression, their high prices often surpass the financial capacity of both patients and healthcare systems. As a result, insurance providers and payers frequently enforce rigorous reimbursement standards, such as necessitating proof of lung function decline prior to approval, which delays the start of treatment and shrinks the eligible patient pool, ultimately lowering revenue potential.

This financial toxicity not only hinders new patient enrollment but also leads to high rates of treatment abandonment. Patients confronted with significant out-of-pocket costs are often compelled to prioritize essential living expenses over medication adherence, resulting in poorer clinical outcomes and decreased drug sales volume. Highlighting this burden, the Pulmonary Fibrosis Foundation noted in 2024 that Medicare beneficiaries in the United States faced an annual out-of-pocket spending cap of roughly $8,000 for prescription drugs before new limits were enacted, demonstrating the severe economic strain on the elderly population most susceptible to the disease. These economic pressures create a restrictive atmosphere that suppresses the widespread uptake of therapeutics, thereby impeding overall market expansion.

Market Trends

The integration of Artificial Intelligence into diagnostic imaging is transforming the Global Idiopathic Pulmonary Fibrosis Market by substituting subjective manual evaluations with automated, quantitative biomarkers that more accurately predict disease progression. These AI-powered tools examine computed tomography scans to measure variations in lung structure, equipping clinicians with reliable data for patient stratification in clinical trials and personalized care. According to a March 2025 report by the National Institutes of Health on highlights from the 'ERS Congress 2024', the AI-derived Weighted Reticulovascular Score (WRVS) showed superior prognostic ability over traditional densitometry, identifying patients with a high mortality risk through a hazard ratio of 4.55.

Additionally, the rise of Next-Generation Mechanism-Specific Therapies marks a critical transition from broad-spectrum antifibrotics to precision agents that target specific pathogenic pathways, such as lysophosphatidic acid signaling. This trend is motivated by the critical need to enhance patient adherence and results via drugs that provide improved safety profiles and targeted efficacy compared to legacy treatments like pirfenidone and nintedanib. As reported by Chest Physician in July 2025 regarding the article 'Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis', the investigational LPA1 antagonist admilparant resulted in a 54% relative risk reduction in lung function decline among idiopathic pulmonary fibrosis patients treated with the 60 mg dose.

Key Market Players

  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Cipla Limited
  • Shionogi & Co., Ltd
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • FibroGen, Inc
  • Pliant Therapeutics, Inc
  • Galecto, Inc.
  • CSL Behring

Report Scope

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Idiopathic Pulmonary Fibrosis Market, By Drug Type

  • Pirfenidone
  • Nintedanib
  • others

Idiopathic Pulmonary Fibrosis Market, By Route of Administration

  • Parenteral
  • Oral
  • Others

Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Idiopathic Pulmonary Fibrosis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Idiopathic Pulmonary Fibrosis Market.

Available Customizations:

Global Idiopathic Pulmonary Fibrosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Idiopathic Pulmonary Fibrosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pirfenidone, Nintedanib, others)
    • 5.2.2. By Route of Administration (Parenteral, Oral, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Idiopathic Pulmonary Fibrosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Idiopathic Pulmonary Fibrosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Idiopathic Pulmonary Fibrosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Idiopathic Pulmonary Fibrosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Idiopathic Pulmonary Fibrosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Idiopathic Pulmonary Fibrosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Idiopathic Pulmonary Fibrosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Idiopathic Pulmonary Fibrosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Idiopathic Pulmonary Fibrosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Boehringer Ingelheim International GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Cipla Limited
  • 15.4. Shionogi & Co., Ltd
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. United Therapeutics Corporation
  • 15.7. FibroGen, Inc
  • 15.8. Pliant Therapeutics, Inc
  • 15.9. Galecto, Inc.
  • 15.10. CSL Behring

16. Strategic Recommendations

17. About Us & Disclaimer